Biblio
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM. Blood Adv. 2024.
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020.
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in D816V-Negative Advanced Systemic Mastocytosis. Cancers (Basel). 2024;16(3).
Importance of adequate diagnostic work-up for correct diagnosis of advanced systemic mastocytosis. J Allergy Clin Immunol Pract. 2020.
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691.
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016.
Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM). J Invest Dermatol. 2021.
Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023;2(6):EVIDoa2200339.